Today: 19 May 2026
Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test
29 April 2026
2 mins read

Lemonade Stock Jumps as Q1 Revenue Surge Sharpens Its 2026 Profit Test

NEW YORK, April 29, 2026, 09:07 (EDT)

Lemonade Inc bumped up its 2026 forecast on Wednesday after reporting a 71% surge in first-quarter revenue and a slimmer net loss, offering investors a new look at the digital insurer’s push to turn speedy premium growth into actual earnings. The numbers landed in an 8-K covering operations and financials, with the shareholder letter tacked on as an exhibit.

This has become a focal point, as Lemonade has long insisted its AI-focused approach to insurance keeps costs below those of legacy insurers. Management reiterated its forecast for a positive adjusted EBITDA in Q4—adjusted EBITDA excludes interest, taxes, depreciation, amortization, and select other expenses, so it isn’t a strict profit metric.

Before the bell, Lemonade shares pointed up. MarketBeat pegged the stock at $69.51 in premarket action—5.6% higher as of 8:38 a.m. Eastern—following results that showed a per-share loss of 47 cents, beating the consensus estimate for a 58-cent loss. Revenue cleared the bar as well, topping the $251.5 million analysts had forecast.

Lemonade posted revenue of $258.0 million, up from $151.2 million a year ago. The company credited the jump to a bigger gross earned premium base and improved premium retention, following a cut in its quota-share reinsurance cession rates. (Reinsurance lets insurers offload some of their risk.)

In-force premium (IFP), which measures annualized premiums from active policies as of quarter-end, jumped 32% to $1.33 billion. The customer base climbed 23%, reaching 3.14 million. Premium per customer was up 7%, now at $424.

Losses shrank, but the company still posted a net loss according to generally accepted accounting principles. Net loss came in at $35.8 million, or 47 cents per share, compared with $62.4 million, or 86 cents a share, a year ago. Adjusted EBITDA loss also narrowed, dropping to $17.1 million from $47.0 million.

Gross profit jumped 159% to $100.1 million, as revenue climbed and the net loss ratio improved by 19 points. Lemonade’s gross loss ratio—a measure of claims costs before reinsurance—fell to 62% from 78%. Net loss ratio dropped to 63%, down from 82%.

Costs moved higher. Operating expense, which strips out net loss and loss-adjustment expense, climbed 25% to $159.3 million, driven mostly by Lemonade’s heavier customer acquisition outlay. The company’s growth spend jumped to $54.3 million from $38.1 million a year ago.

Chief Financial Officer Tim Bixby told analysts revenue climbed “roughly 40 percentage points faster than IFP.” CEO Daniel Schreiber reiterated Lemonade’s outlook for a “positive full quarter of EBITDA” in Q4. Co-founder Shai Wininger, for his part, noted that retention pressure from homeowners non-renewals “should start to fade.” Investing.com Canada

The company is forecasting 2026 revenue between $1.197 billion and $1.203 billion, and expects an adjusted EBITDA loss ranging from $47 million to $51 million. Looking at the second quarter, revenue is pegged between $287 million and $290 million, with IFP seen at $1.428 billion to $1.433 billion.

Lemonade took the opportunity in its letter to line up its automation numbers against those of bigger rivals. According to the company, its IFP per employee climbed past $1 million—landing Lemonade in the same zone as Progressive, Allstate, and GEICO on that metric. The comparison, though, came from Lemonade itself and wasn’t based on any outside assessment.

Growth in newer segments still figures into the story. Pet insurance—now Lemonade’s biggest line—crossed $500 million in IFP early in the second quarter. Car IFP jumped 60% from a year ago. Lemonade also reported that early conversion rates for its autonomous-car product were roughly 70% higher than what it saw for the non-autonomous version.

Plenty of variables could shake things up. Lemonade flagged possible deviations from its forecast, pointing to past losses, sticky customer retention issues, the wild card of reinsurance—both in terms of cost and supply—plus claims management, regulatory hurdles tied to AI and telematics, and the pressure to maintain enough capital.

Lemonade pitches itself as an AI-first insurance carrier, not just a broker, with products covering renters, homeowners, car, pet, and life insurance in both the U.S. and Europe. The company now faces a bigger challenge: can it sustain its growth pace as it leans into higher acquisition costs, mounting weather-related claims, and tighter oversight of its automated underwriting?

Stock Market Today

  • Institutional Firms and Insiders Reduce Alphabet Stock Holdings
    May 19, 2026, 2:26 PM EDT. Several institutional investors and corporate insiders have recently sold shares of Alphabet Inc., the parent company of Google, as revealed by SEC filings. These disclosures indicate a notable decline in equity holdings by major shareholders, which could signal concerns or portfolio rebalancing. Alphabet's stock performance may be influenced by this wave of selling amidst broader market dynamics.

Latest articles

Amazon Stock Drops, But the Bigger $200 Billion AI Question Isn’t Going Away

Amazon Stock Drops, But the Bigger $200 Billion AI Question Isn’t Going Away

19 May 2026
Amazon shares fell 2.3% to $258.73 Tuesday, underperforming the S&P 500 and Nasdaq as investors trimmed tech holdings ahead of Nvidia’s earnings. AWS revenue jumped 28% to $37.6 billion last quarter, but Amazon’s free cash flow dropped to $1.2 billion over the past year from $25.9 billion, reflecting heavy AI spending.
Astera Labs Moves Higher as Wall Street Eyes Next AI Bottleneck

Astera Labs Moves Higher as Wall Street Eyes Next AI Bottleneck

19 May 2026
Astera Labs shares surged 15.2% to $248.36 Tuesday after Evercore ISI raised its price target and management highlighted rising AI data-center demand. CEO Jitendra Mohan said revenue grew from $65 million at its 2024 IPO to $308 million last quarter. The company’s market value neared $45 billion, with shares trading at about 168 times earnings. One customer accounted for over 70% of projected 2025 revenue.
Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

Recursion Stock Slumps to 52-Week Low as Traders Eye FDA News

19 May 2026
Recursion Pharmaceuticals shares fell 2.2% to $2.825 Tuesday, hitting a 52-week low of $2.77, after reporting first-quarter revenue of $6.47 million, down from $14.75 million a year earlier. Net loss narrowed to $117.5 million. Early clinical data for REC-1245 showed no dose-limiting toxicities in 16 solid-tumor patients. The company ended March with $665.2 million in cash.
Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge
Previous Story

Biogen Cuts 2026 Profit Forecast After Q1 Beat as Leqembi Sales Surge

Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset
Next Story

Generac Stock Jumps After Data Center Backlog Forces a 2026 Forecast Reset

Go toTop